ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis

Journal of Immunology

Volumn 182, Issue 9, 2009, Pages 5374-5381

  Martins, Vanessa ^a   Valença, Samuel S ^b   Farias Filho, Francisco A ^c   Molinaro, Raphael ^a   Simões, Rafael L ^b   Ferreira, Tatiana P T ^c   E Silva, Patrícia M R ^c   Hogaboam, Cory M ^d   Kunkel, Steven L ^d   Fierro, Iolanda M ^b   Canetti, Claudio ^a   Benjamim, Claudia F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ACTIN; ASPIRIN TRIGGERED LIPOXIN A 4; BLEOMYCIN; ICOSANOID; LIPOXIN A; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 16 (4 FLUOROPHENOXY)LIPOXIN A4; 16-(4-FLUOROPHENOXY)LIPOXIN A4; ANTIFIBRINOLYTIC AGENT; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG PARENCHYMA; LUNG RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; INNATE IMMUNITY; LUNG FUNCTION TEST; MORTALITY; PATHOPHYSIOLOGY; SURVIVAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; ASPIRIN; BLEOMYCIN; IMMUNITY, INNATE; LIPOXINS; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SURVIVAL ANALYSIS;

EID: 66949129763     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802259     Document Type: Article

References (68)

1. American Thoracic Society. 2000. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am. J. Respir. Crit. Care Med. 161: 646-664. (Pubitemid 30129480)
2. Gabbiani, G. 1981. The myofibroblast: a key cell for wound healing and fibrocontractive diseases. Prog. Clin. Biol. Res. 54: 183-194.
3. Kawanami, O., V. J. Ferrans, and R. G. Crystal. 1982. Structure of alveolar epithelial cells in patients with fibrotic lung disorders. Lab Invest. 46: 39-53. (Pubitemid 12167015)
4. Kuhn, C. 1993. The pathogenesis of pulmonary fibrosis. Monogr. Pathol. 78-92.
5. Chua, F., J. Gauldie, and G. J. Laurent. 2005. Pulmonary fibrosis: searching for model answers. Am. J. Respir. Cell Mol. Biol. 33: 9-13. (Pubitemid 40961008)
6. Gross, T. J., and G. W. Hunninghake. 2001. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345: 517-525.
7. Dempsey, O. J. 2006. Clinical review: idiopathic pulmonary fibrosis-past, present and future. Respir. Med. 100: 1871-1885.
8. Oikonomou, N., V. Harokopos, J. Zalevsky, C. Valavanis, A. Kotanidou, D. E. Szymkowski, G. Kollias, and V. Aidinis. 2006. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS ONE. 1: e108.
9. Sleijfer, S. 2001. Bleomycin-induced pneumonitis. Chest 120: 617-624.
10. Adamson, I. Y. 1984. Drug-induced pulmonary fibrosis. Environ. Health Perspect. 55: 25-36.
11. Delaunois, L. M. 2004. Mechanisms in pulmonary toxicology. Clin. Chest Med. 25: 1-14.
12. Hay, J., S. Shahzeidi, and G. Laurent. 1991. Mechanisms of bleomycin-induced lung damage. Arch. Toxicol. 65: 81-94.
13. Downey, D. G., S. Brockbank, S. L. Martin, M. Ennis, and J. S. Elborn. 2007. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr. Pulmonol. 42: 729-735.
14. Dury, S. 2006. Treatment of idiopathic pulmonary fibrosis. Rev. Mal. Respir. 23: 5S87-5S91.
15. Mapel, D. W., J. M. Samet, and D. B. Coultas. 1996. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 110: 1058-1067.
16. Bouros, D., and K. M. Antoniou. 2005. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur. Respir. J. 26: 693-702. (Pubitemid 41448670)
17. Daniels, C. E., and J. H. Ryu. 2006. Treatment of idiopathic pulmonary fibrosis. Semin. Respir. Crit. Care Med. 27: 668-676.
18. Kuwano, K., N. Hagimoto, and N. Hara. 2001. Molecular mechanisms of pulmonary fibrosis and current treatment. Curr. Mol. Med. 1: 551-573. (Pubitemid 33772035)
19. Fierro, I. M., and C. N. Serhan. 2001. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz. J. Med. Biol. Res. 34: 555-566.
20. Serhan, C. N. 2005. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids 73: 141-162.
21. Claria, J., and C. N. Serhan. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92: 9475-9479.
22. 4 12-hydroxydehydrogenase in inflammation. J. Biol. Chem. 275: 25372-25380.
23. McMahon, B., and C. Godson. 2004. Lipoxins: endogenous regulators of inflammation. Am. J. Physiol. 286: F189-F201.
24. Vachier, I., C. Bonnans, C. Chavis, M. Farce, P. Godard, J. Bousquet, and P. Chanez. 2005. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J. Allergy Clin. Immunol. 115: 55-60. (Pubitemid 40075421)
25. 4. J. Pharmacol. Exp. Ther. 300: 385-392.
26. Mitchell, S., G. Thomas, K. Harvey, D. Cottell, K. Reville, G. Berlasconi, N. A. Petasis, L. Erwig, A. J. Rees, J. Savill, et al. 2002. Lipoxins, aspirintriggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13: 2497-2507.
27. Clish, C. B., J. A. O'Brien, K. Gronert, G. L. Stahl, N. A. Petasis, and C. N. Serhan. 1999. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA 96: 8247-8252.
28. Levy, B. D., and C. N. Serhan. 2003. Exploring new approaches to the treatment of asthma: potential roles for lipoxins and aspirin-triggered lipid mediators. Drugs Today 39: 373-384.
29. Karp, C. L., L. M. Flick, K. W. Park, S. Softic, T. M. Greer, R. Keledjian, R. Yang, J. Uddin, W. B. Guggino, S. F. Atabani, et al. 2004. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5: 388-392.
30. Valenca, S. S., K. da Hora, P. Castro, V. G. Moraes, L. Carvalho, and L. C. Porto. 2004. Emphysema and metalloelastase expression in mouse lung induced by cigarette smoke. Toxicol. Pathol. 32: 351-356. (Pubitemid 38692007)
31. Ramirez, A. M., Z. Shen, J. D. Ritzenthaler, and J. Roman. 2006. Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF-β signaling through Smad3-dependent and -independent pathways. Am. J. Transplant. 6: 2080-2088.
32. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
33. Fonseca, B. P., P. C. Olsen, L. P. Coelho, T. P. Ferreira, H. S. Souza, M. A. Martins, and J. P. Viola. 2009. NFAT1 transcription factor regulates pulmonary allergic inflammation and airway responsiveness. Am. J. Respir. Cell Mol. Biol. 40: 66-75.
34. Trujillo, G., E. C. O'Connor, S. L. Kunkel, and C. M. Hogaboam. 2008. A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 172: 1209-1221. (Pubitemid 351671535)
35. Woessner, J. F., Jr. 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93: 440-447.
36. Crestani, B., S. Marchand-Adam, A. Fabre, M. Dehoux, and P. Soler. 2007. Mechanisms in pulmonary fibrosis. Rev. Prat. 57: 2222-2226.
37. Pardo, A., and M. Selman. 2006. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc. Am. Thorac. Soc. 3: 383-388. (Pubitemid 43845417)
38. Scotton, C. J., and R. C. Chambers. 2007. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132: 1311-1321. (Pubitemid 47621009)
39. Wynn, T. A. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117: 524-529.
40. Wynn, T. A. 2008. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214: 199-210.
41. Meneghin, A., and C. M. Hogaboam. 2007. Infectious disease, the innate immune response, and fibrosis. J. Clin. Invest. 117: 530-538. (Pubitemid 46348507)
42. Pardo, A., and M. Selman. 2002. Molecular mechanisms of pulmonary fibrosis. Front. Biosci. 7: 1743-1761.
43. Izumo, T., M. Kondo, and A. Nagai. 2007. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci. 80: 1882-1886. (Pubitemid 46560739)
44. Bonnans, C., D. Gras, C. Chavis, B. Mainprice, I. Vachier, P. Godard, and P. Chanez. 2007. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. Biomed. Pharmacother. 61: 261-267. (Pubitemid 46891725)
45. Bonnans, C., I. Vachier, C. Chavis, P. Godard, J. Bousquet, and P. Chanez. 2002. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med. 165: 1531-1535. (Pubitemid 34606669)
46. Edenius, C., M. Kumlin, T. Bjork, A. Anggard, and J. A. Lindgren. 1990. Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett. 272: 25-28. (Pubitemid 20348973)
47. 4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am. Rev. Respir. Dis. 141: 1453-1458.
48. Levy, B. D., M. Romano, H. A. Chapman, J. J. Reilly, J. Drazen, and C. N. Serhan. 1993. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 92: 1572-1579.
49. Parkinson, J. F. 2006. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm. Allergy Drug Targets 5: 91-106.
50. Vachier, I., P. Chanez, C. Bonnans, P. Godard, J. Bousquet, and C. Chavis. 2002. Endogenous anti-inflammatory mediators from arachidonate in human neutrophils. Biochem. Biophys. Res. Commun. 290: 219-224. (Pubitemid 34694486)
51. Chiang, N., E. A. Bermudez, P. M. Ridker, S. Hurwitz, and C. N. Serhan. 2004. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101: 15178-15183. (Pubitemid 39391738)
52. Fukunaga, K., P. Kohli, C. Bonnans, L. E. Fredenburgh, and B. D. Levy. 2005. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174: 5033-5039. (Pubitemid 40504588)
53. Levy, B. D., G. T. De Sanctis, P. R. Devchand, E. Kim, K. Ackerman, B. A. Schmidt, W. Szczeklik, J. M. Drazen, and C. N. Serhan. 2002. Multipronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med. 8: 1018-1023. (Pubitemid 35033707)
54. 2 signaling in RAW246.7 cells in vitro and bleomycin-induced lung fibrosis in vivo. Biomed. Pharmacother. 58: 381-387.
55. 4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am. J. Pathol. 167: 683-694.
56. 4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. Kidney Int. 69: 248-256.
57. Phan, S. H. 2002. The myofibroblast in pulmonary fibrosis. Chest 122(Suppl. 6): 286S-289S.
58. Laurent, G. J., R. J. McAnulty, M. Hill, and R. Chambers. 2008. Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis. Proc. Am. Thorac. Soc. 5: 311-315.
59. Strieter, R. M. 2008. What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc. Am. Thorac. Soc. 5: 305-310.
60. Caraci, F., E. Gili, M. Calafiore, M. Failla, C. La Rosa, N. Crimi, M. A. Sortino, F. Nicoletti, A. Copani, and C. Vancheri. 2008. TGF-β1 targets the GSK-3β/β-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol. Res. 57: 274-282.
61. Higashiyama, H., D. Yoshimoto, T. Kaise, S. Matsubara, M. Fujiwara, H. Kikkawa, S. Asano, and M. Kinoshita. 2007. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp. Mol. Pathol. 83: 39-46. (Pubitemid 46842964)
62. Moore, B. B., and C. M. Hogaboam. 2008. Murine models of pulmonary fibrosis. Am. J. Physiol. 294: L152-L160.
63. 4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. Am. J. Respir. Cell Mol. Biol. 34: 65-72.
64. 4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J. Biol. Chem. 275: 27566-27575.
65. Mitchell, D., K. Rodgers, J. Hanly, B. McMahon, H. R. Brady, F. Martin, and C. Godson. 2004. Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am. J. Pathol. 164: 937-946. (Pubitemid 38235475)
66. 4 inhibits TNF-α-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int. 68: 35-46.
67. 4 induces apoptosis in rat renal interstitial fibroblasts. Prostaglandins Leukot. Essent. Fatty Acids. 73: 127-137.
68. 4 inhibits IL-1β-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol. 164: 2660-2666.